Dr. Reddy's Laboratories shares are trading higher after the company and Alvotech signed an agreement to co-develop and commercialize a biosimilar candidate to Keytruda. Additionally, HSBC upgraded the stock from Hold to Buy and raised its price t...

+0.21% Pre

Dr. Reddy's Laboratories Ltd. Sponsored ADR

RDY

0.00

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Pacira Biosciences Study Finds Iovera° Superior to Radiofrequency Ablation for Chronic Low Back Pain

Dr. Reddy's Laboratories' Aurigene Oncology Unit Results From 1st Two Groups Of Phase 1 Clinical Study Of AUR112 Demonstrates Safety, Meaningful Clinical Activity With Objective Responses Observed Across Multiple Lymphoma Subtypes

Metavia Inc. Announces 1-for-11 Reverse Stock Split

B of A Securities Maintains Buy on Janux Therapeutics, Lowers Price Target to $49

Mizuho Upgrades Belite Bio to Outperform, Raises Price Target to $194

Day's Trending USA Stocks | Capricor Therapeutics, Inc.: Overnight gain 371.1%, Breakthrough in Duchenne muscular dystrophy trial boosts investor confidence, driving stock surge.

Breakthrough And Pullback | 9 Stocks Deserve Close Attention: TTI, NESR And More

Tilray (TLRY) Reverse Split Triggers Volatility: What the New Capital Structure Means for Valuation